Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Date:1/27/2010

g proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... company, is delighted to announce its financial results ... which includes revenue for three months of $2,180,276 ... from advanced wound care product sales for the ... 24% to $1,742,672 compared to $1,400,065 for the ...
(Date:5/29/2015)... 2015  Epic Sciences announced today that the company ... castrate resistant prostate cancer patients, at the 2015 ... Oncology. This application expands the investigational utility of ... platform to characterize circulating tumor cell (CTC) genomic ... have heterogeneous clonal CTC populations harboring separate genetic ...
(Date:5/29/2015)... , May 29, 2015  World-renowned prostate surgeon and New ... on the benefit of MR/Ultrasound Fusion-Guided Biopsy for ... Prostate Cancer Center at Lenox Hill Hospital is ... System in New York City . We,ve ... risk prostate cancers. The use of an MRI makes for ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
(Date:5/29/2015)... North Carolina (PRWEB) May 29, 2015 ... confirmed that the newest Red Hot & Blue restaurant at ... business on Thursday, May 7, 2015. “The Red Hot & ... center for 18 years, but we have moved to a ... are now in the middle of all the activities on ...
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... May 29, 2015 World Patent Marketing, ... announces that it has signed a 10 year licensing ... that aims to let people learn about any topic ... time. , "This is an exciting day for World ... Scott J. Cooper, CEO and Creative Director of World ...
(Date:5/29/2015)... May 29, 2015 The print component ... a circulation of approximately 250,000 and an estimated readership ... a vast social media strategy, and across a network ... the digital version of the campaign, click here. ... print publication. Inside, the actress, model and producer details ...
(Date:5/29/2015)... May 29, 2015 The campaign focuses ... as a number of specific concerns within, including the ... and mental health in the workplace. We are encouraged ... The campaign also brings special focus to people living ... speak up and seek help from healthcare professionals and ...
Breaking Medicine News(10 mins):Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2
... Regions, These Markets Remain Stable, According to New ... HealthLeaders-InterStudy, a leading provider of managed care ... many regions of the country have halted because ... in Buffalo, N.Y., and Baton Rouge, La., are ...
... Calif., Jan. 26 Doctors at the,Northwoods Cancer ... patients,using new RapidArc radiotherapy technology from Varian Medical ... a retired machinist fighting prostate cancer, is,among the ... speed and accuracy of,RapidArc, which delivers image-guided intensity-modulated ...
... Jan. 26 ChromaDex Corporation, (OTC Bulletin Board: ... contract research, announced today that Nutrition Business Journal, ... care magazine, selected the Company as one of ... its achievement in setting stevia standards as part ...
... will add new technology to help ORBIS train doctors ... ORBIS International , a nonprofit ... donated PASCAL photocoagulator as part of a new partnership ... to treat a variety of retinal diseases, PASCAL dramatically ...
... Jan. 26 FluoroPharma Inc., a company ... Positron Emission Tomography (PET) market, announced today ... Office issued U.S. Patent No. 7,438,891, covering ... F18 labeled 2-fluorodeoxy-D-glucose (FDG). This patent, exclusively ...
... N.J., Jan. 26 Quest Diagnostics Incorporated (NYSE: ... of diagnostic testing, information and services, announced that ... in share repurchases. The company had approximately 190 ... 2008."This repurchase program demonstrates confidence in our performance ...
Cached Medicine News:Health News:Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience 2Health News:Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience 3Health News:A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Health News:A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 2Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 3Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 4Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Quest Diagnostics' Board Authorizes $500 Million in Share Repurchases 2
... 3Z slit lamp is designed to for ... ready slit lamp offers the popular horizontal ... to the ReSeeVit family of slit lamps ... market to capture clear, crisp digital images ...
... system combines continuous access, random ... a broad testing menu. AxSYM ... clinical laboratories to process a ... as well as adding tests ...
... an automated, multiparametric immunoassay system. ... stores the calibration in the ... cost-per-patient result. Plus, ease ... labor cost is also optimized. ...
... AIA-1800 is the newest and most advanced ... The AIA-1800 launches with a full ... markers, thyroid, reproductive, cardiac, and anemia assays. ... throughput, bar-coded primary tube sampling, auto dilution, ...
Medicine Products: